Andrea Lobo,  —

People with Friedreich’s ataxia (FA) may have elevated blood levels of cardiac troponin I and T, markers of heart damage, without signs of heart dysfunction, a study suggests. Being younger, female, or having a higher number of GAA repeats, the main type of FA-causing mutation, was associated with higher…

The U.S. Food and Drug Administration (FDA) has removed the partial hold on the clinical development of nomlabofusp, an experimental treatment for Friedreich’s ataxia (FA). The decision followed a review of data from a Phase 2 dose exploration trial (NCT05579691), which showed the treatment was well tolerated…

The U.S. Food and Drug Administration (FDA) has put Lexeo Therapeutics’ LX2006, a gene therapy candidate for heart disease in people with Friedreich’s ataxia (FA), on the fast track for development. The award of fast track status aims to expedite the development and regulatory review of investigational therapies…

The Committee for Medicinal Products for Human Use (CHMP) — an arm of the European Medicines Agency — is recommending the approval of Skyclarys (omaveloxolone) for treating Friedreich’s ataxia (FA) in people ages 16 and older in the European Union. The European Commission now will review the CHMP’s…

A first group of patients has been treated with LX2006, an investigational gene therapy for heart disease in people with Friedreich’s ataxia (FA), in a Phase 1/2 clinical trial and dosing has begun in a second group. LX2006 has been well tolerated and not associated with unexpected…

Short-read genome sequencing (SR-GS), a test that can identify difficult-to-detect mutations, may help to correctly diagnose atypical Friedreich’s ataxia (FA) in people whose symptoms and family history are not indicative of FA, a study in Germany shows. The study, “Short-read genome sequencing allows ‘en route’ diagnosis of patients…